Common Contracts
5 similar Asset Purchase Agreement contracts by Cover All Technologies Inc, Hallador Energy Co, Orasure Technologies Inc, others
Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial StatementsAsset Purchase Agreement • August 21st, 2023 • Precision Biosciences Inc • Biological products, (no disgnostic substances)
On August 15, 2023, Precision BioSciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Imugene Limited, an Australian corporation (“Imugene Limited”), and its wholly owned subsidiary Imugene (USA) Inc. (“Imugene US”), a Nevada corporation (collectively, “Imugene”). Pursuant to and simultaneously with the execution of the Purchase Agreement, on August 15, 2023 (the “Closing Date”), Imugene US acquired the manufacturing infrastructure to the Company’s CAR T program that uses azer-cel for the potential treatment of relapsed or refractory non-Hodgkin lymphoma, which includes the Company’s MCAT facility, certain contracts of the Company with respect to the MCAT facility and the Company’s azer-cel program, including the lease to the MCAT facility, and related equipment, supplies, azer-cel clinical trial inventory and other assets related to the Company’s CAR T cell therapy platform (the “Acquisition").
Hallador Energy Company Unaudited Pro Forma Condensed Combined Financial InformationAsset Purchase Agreement • January 6th, 2023 • Hallador Energy Co • Bituminous coal & lignite mining
On February 14, 2022, Hallador Energy Company (“Hallador” or the “Company”), through its subsidiary Hallador Power Company, LLC, a Delaware limited liability company, signed an Asset Purchase Agreement (“APA”), with Hoosier Energy Rural Electric Cooperative, Inc. (“Seller” or “Hoosier”), a rural electric membership corporation organized and existing under the laws of the state of Indiana. Pursuant to the APA, the Company acquired the Merom one gigawatt powerplant located on 800 acres in Sullivan County, Indiana, (the “Merom Plant”), along with: equipment and machinery in the Merom Plant; materials inventory; a coal combustion certified coal ash landfill; and coal inventory (collectively, the “Merom Plant Acquisition”). The Company completed the Merom Plant Acquisition on October 21, 2022 pursuant to the APA.
Unaudited Pro Forma Condensed Consolidated Financial InformationAsset Purchase Agreement • January 14th, 2022 • VYNE Therapeutics Inc. • Pharmaceutical preparations
On January 12, 2022 (the “Effective Date”), VYNE Therapeutics Inc. (the “Company” or “VYNE”) entered into an Asset Purchase Agreement (the “Agreement”) with Journey Medical Corporation (“Journey” or “Buyer”) pursuant to which the Company sold its Molecule Stabilizing Technology (MSTTM) franchise, including AMZEEQ®, ZILXI®, and FCD105 (the “MST Franchise”), to Journey. The assets include certain contracts, including the license agreement with Cutia Therapeutics (HK) Limited (“Cutia”), inventory and intellectual property related to the MST Franchise (together, the “Assets”). Pursuant to the Agreement, the Buyer assumed certain liabilities of the MST Franchise including, among others, those arising from VYNE’s patent infringement suit initiated against Padagis Israel Pharmaceuticals Ltd. There were no current or long-term liabilities recorded by the Company which were transferred to the Buyer. The sale was consummated concurrently with the execution of the Purchase Agreement.
ORASURE TECHNOLOGIES, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTSAsset Purchase Agreement • August 19th, 2019 • Orasure Technologies Inc • Surgical & medical instruments & apparatus
On August 15, 2019, OraSure Technologies, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) between the Company and CryoConcepts, LP (“CryoConcepts”), pursuant to which the Company has agreed to sell certain assets associated with the Company’s cryosurgical systems business (the “Business”), including the Company’s professional Histofreezer product line and several private label cryosurgical products sold in the consumer market, along with related patents and trademarks, customer contracts and goodwill associated with the Business, for an aggregate purchase price of $12.0 million in cash (the “Sale”).
COVER-ALL TECHNOLOGIES INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTSAsset Purchase Agreement • March 19th, 2012 • Cover All Technologies Inc • Services-prepackaged software
On December 30, 2011 (the “Closing Date”), Cover-All Systems, Inc. (the “Company”), a Delaware corporation and wholly-owned subsidiary of Cover-All Technologies Inc., a Delaware corporation (the “Registrant”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ho’ike Services, Inc., dba BlueWave Technology, a Hawaii corporation (“Seller”). Under the terms of the Purchase Agreement, the Company purchased from Seller certain of the assets (excluding working capital) (the “Assets”) and assumed certain liabilities (the “Assumed Liabilities”) of Seller’s business of developing and servicing enterprise claims management software for use in the property and casualty insurance industry, including for use by property and casualty insurance companies, third party administrators, managing general agents, self-insured employers and state funds, and providing certain services related thereto (the “Business”), which Business Seller had marketed under the name “PipelineClaims” (
